Isodiol International Inc. Signs Definitive Agreement to Acquire Bradley’s Bioscience Inc., and Closes Strategic Financing

VANCOUVER, British Columbia, Nov. 22, 2017 -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a definitive agreement in connection with its previously announced (https://isodiol.com/isodiol-international-signs-letter-intent-acquire-bradleys-bioscience/) Letter of Intent (LOI) to acquire Bradley’s Bioscience Inc., a leading manufacturer and distributer of hemp oil and nicotine e-liquids.

“The acquisition of Bradley’s Bioscience, a market poised to be a $61.4 billion-dollar industry by 2025 is another major milestone for the Company,” said Marcos Agramont, CEO of Isodiol. “Not only does this allow the Company to penetrate a new market, but we are now also able to provide consumers with a safer alternative to smoking.  Overall, we believe Bradley’s Bioscience is a perfect fit with Isodiol and our long-term vision and we are very pleased to be moving forward with this agreement.”

“As we previously stated, Isodiol has been instrumental in our success over the years,” said Joe Bradley, CEO of Bradley’s Bioscience.   “We could not be happier to partner with a company that shares our vision in affecting lives in a positive way and we look forward to continuing to share our message with consumers and the general public.”

As part of this agreement, the Company will issue Bradley’s Bioscience Inc. $380,000 USD in stock, which totaled 1,540,281 shares, subject to a 36-month escrow.

The Company has also completed an additional round of financing that was initiated prior to our recent escalation in stock price. The intent of the raise is to fund recent acquisitions and allow the company to remain flexible in M&A transactions and future international expansion.  The Company raised a total of $6,087,047 CAD by issuing 24,348,187 units with a full one-year warrant at $.75.  All financing units are subject to a 4 month hold period.

For more information on Isodiol, please visit www.isodiol.com
For more information on Bradley’s Bioscience, please visit www.bradleysbrand.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and aggressively continuing international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
[email protected]
www.isodiol.com

MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
[email protected]

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.